166 related articles for article (PubMed ID: 8298445)
1. Tamoxifen in premalignant and pre-invasive breast cancer.
Neven P
Eur J Cancer Prev; 1993 Nov; 2 Suppl 3():147-51. PubMed ID: 8298445
[No Abstract] [Full Text] [Related]
2. [Hormone therapy as primary therapy of operable breast carcinoma in elderly patients].
Foudraine NA; Verhoef CG; Burghouts TM
Ned Tijdschr Geneeskd; 1993 Nov; 137(46):2345-7. PubMed ID: 8264814
[No Abstract] [Full Text] [Related]
3. National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.
Vogel VG; Costantino JP; Wickerham DL; Cronin WM
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):495S-501S. PubMed ID: 12538506
[TBL] [Abstract][Full Text] [Related]
4. Impact of randomized clinical trial results in the national comprehensive cancer network on the use of tamoxifen after breast surgery for ductal carcinoma in situ.
Yen TW; Kuerer HM; Ottesen RA; Rouse L; Niland JC; Edge SB; Theriault RL; Weeks JC
J Clin Oncol; 2007 Aug; 25(22):3251-8. PubMed ID: 17577019
[TBL] [Abstract][Full Text] [Related]
5. [Lobular carcinoma-in-situ and ductal hyperplasia of breast].
Fu L
Zhonghua Bing Li Xue Za Zhi; 2006 Jan; 35(1):4-7. PubMed ID: 16608640
[No Abstract] [Full Text] [Related]
6. [Receptor (ER, PgR) levels as prognostic factors in the endocrine therapy of pre- and post-menopausal patients with stage III infiltrative ductal and lobular cancer of the breast].
Calzada L; Salazar EL; Pedron Nuevo N
Ginecol Obstet Mex; 1996 Mar; 64():135-9. PubMed ID: 8729191
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen in ductal carcinoma in situ.
Daly MB
Semin Oncol; 2006 Dec; 33(6):647-9. PubMed ID: 17145343
[TBL] [Abstract][Full Text] [Related]
8. Ductal carcinoma in situ.
Venniyoor A
Aust Fam Physician; 2006 May; 35(5):278-9; author reply 279. PubMed ID: 16708448
[No Abstract] [Full Text] [Related]
9. 'Good prognosis tumours' in breast cancer screening.
Birch D; Payne M; Chia Y; McPherson S
Ann R Coll Surg Engl; 1995 May; 77(3):185-7. PubMed ID: 7598415
[TBL] [Abstract][Full Text] [Related]
10. Two case reports of ovarian cancer after long-term tamoxifen treatment for breast cancer.
Ohara N; Kobayashi A
J Obstet Gynaecol; 2002 Sep; 22(5):572-3. PubMed ID: 12521448
[No Abstract] [Full Text] [Related]
11. [A case of combined noninvasive ductal and lobular carcinoma].
Nagashima S; Sakurai K; Suzuki S; Hara Y; Waga E; Iizuka M; Fuchinoue T; Hirano T; Enomoto K; Tani M; Masuda S; Amano S; Koshinaga T
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2033-5. PubMed ID: 23267967
[TBL] [Abstract][Full Text] [Related]
12. Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention.
Goldenberg VK; Seewaldt VL; Scott V; Bean GR; Broadwater G; Fabian C; Kimler B; Zalles C; Lipkus IM
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1032-4. PubMed ID: 17507634
[TBL] [Abstract][Full Text] [Related]
13. [Is low-dose tamoxifen an effective therapy for breast carcinoma in situ?].
Ivanova OA; Zhil'tsova EK; Barash NIu; Ivanov VG; Ermachenkova AM
Vopr Onkol; 2011; 57(5):601-3. PubMed ID: 22238929
[No Abstract] [Full Text] [Related]
14. Designer estrogens: breast cancer benefit, remaining questions.
Health News; 1999 Jul; 5(9):6. PubMed ID: 10480007
[No Abstract] [Full Text] [Related]
15. Sentinel lymph node biopsy for breast cancer.
Swanson JO
J Insur Med; 2001; 33(2):195-7. PubMed ID: 11510518
[TBL] [Abstract][Full Text] [Related]
16. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
17. [Endometriosis in tamoxifen therapy].
Fuith LC; Pflanzl W
Geburtshilfe Frauenheilkd; 1995 Jun; 55(6):354-5. PubMed ID: 7657147
[TBL] [Abstract][Full Text] [Related]
18. Uterine sarcoma after tamoxifen therapy for breast cancer.
Samuji M; O'Sullivan R; Shireen R
Ir Med J; 2013 Sep; 106(8):246. PubMed ID: 24282897
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer.
Esslimani-Sahla M; Simony-Lafontaine J; Kramar A; Lavaill R; Mollevi C; Warner M; Gustafsson JA; Rochefort H
Clin Cancer Res; 2004 Sep; 10(17):5769-76. PubMed ID: 15355905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
